Dyslipidemia, Obesity, and Ethnicity in Mexican Children

Costa-Urrutia, Paula; Colistro, Valentina; Franco‐Trecu, Valentina; Granados, Julio; Fariña, Rafael Álvarez; Rodríguez-Arellano, Martha Eunice

doi:10.3390/ijerph182312659

Cited by 11 publications

(8 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is a close relationship between obesity and abnormal lipid metabolism. Many studies have revealed a close correlation between high BMI and abnormal lipid metabolism ( 32 , 33 ). In the present study, we found a significant association between high BMI and abnormal lipid metabolism only in female MDD patients with abnormal glucose metabolism.…”

Section: Discussionmentioning

confidence: 99%

Prevalence and correlates of dyslipidemia in first-episode and drug-naïve major depressive disorder patients with comorbid abnormal glucose metabolism: Sex differences

et al. 2023

View full text Add to dashboard Cite

BackgroundLipid metabolism is associated with glucose metabolism, but whether there are variations between sexes in risk factors and prevalence of abnormal lipid metabolism in major depressive disorder (MDD) patients with glucose metabolism abnormalities remains ambiguous. In the present study, the frequency and risk factors of dyslipidemia in first-episode and drug-naïve (FEDN) MDD patients with dysglycemia were examined according to sex.MethodsOne thousand seven hundred and eighteen FEDN MDD patients were recruited and their demographic data, clinical data, various biochemical indicators and scale assessment scores including 17-item Hamilton Rating Scale for Depression (HAMD-17), 14-item Hamilton Anxiety Rating Scale (HAMA-14), and positive subscale of the Positive and Negative Syndrome Scale (PANSS) were collected.ResultsThe prevalence of abnormal lipid metabolism in both male and female MDD patients with abnormal glucose metabolism was higher than that in patients without abnormal glucose metabolism. Among male MDD patients with abnormal glucose metabolism, TC was positively correlated with HAMD score, TSH and TgAb levels, but negatively correlated with PANSS positive subscale scores. LDL-C was positively correlated with TSH and BMI, but negatively correlated with PANSS positive subscale scores. HDL-C was negatively correlated with TSH levels. Among females, TC was positively correlated with HAMD score, TSH, and BMI, but negatively correlated with PANSS positive subscale score. LDL-C was positively correlated with HADM score and negatively correlated with FT3 level. HDL-C was negatively correlated with TSH and BMI levels.ConclusionThere are sex differences in the correlated factors of lipid markers in MDD patients with impaired glucose.

show abstract

Section: Discussionmentioning

confidence: 99%

Prevalence and correlates of dyslipidemia in first-episode and drug-naïve major depressive disorder patients with comorbid abnormal glucose metabolism: Sex differences

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Obesity is usually accompanied by dyslipidemias, i.e., alterations in lipid metabolism, such as hypercholesterolemia, hypertriglyceridemia, increased LDL-c, decreased HDL-c and increased circulating free fatty acids [ 61 , 62 ]. These complications increase the individual’s cardiometabolic risk; thus, addressing them is often carried out as part of an obesity treatment [ 63 ].…”

Section: Effects Of Naringenin Against the Various Components Of Obesitymentioning

confidence: 99%

Could Naringenin Participate as a Regulator of Obesity and Satiety?

et al. 2023

View full text Add to dashboard Cite

Obesity is a serious health problem worldwide, since it is associated with multiple metabolic disorders and complications such as cardiovascular disease, type 2 diabetes, fatty liver disease and overall metabolic dysfunction. Dysregulation of the hunger–satiety pathway, which includes alterations of central and peripheral signaling, explains some forms of obesity by favoring hyperphagia and weight gain. The present work comprehensively summarizes the mechanisms by which naringenin (NAR), a predominant flavanone in citrus fruits, could modulate the main pathways associated with the development of obesity and some of its comorbidities, such as oxidative stress (OS), inflammation, insulin resistance (IR) and dyslipidemia, as well as the role of NAR in modulating the secretion of enterohormones of the satiety pathway and its possible antiobesogenic effect. The results of multiple in vitro and in vivo studies have shown that NAR has various potentially modulatory biological effects against obesity by countering IR, inflammation, OS, macrophage infiltration, dyslipidemia, hepatic steatosis, and adipose deposition. Likewise, NAR is capable of modulating peptides or peripheral hormones directly associated with the hunger–satiety pathway, such as ghrelin, cholecystokinin, insulin, adiponectin and leptin. The evidence supports the use of NAR as a promising alternative to prevent overweight and obesity.

show abstract

“…[7,8] Lipids (mainly triglycerides) represent a major source of calories in most Western diets. [9][10][11] Lipids are mainly digested in the small intestine, duodenum and jejunum, [12,13] simultaneously using components secreted by the pancreas and gallbladder, such as bile salts and pancreatic enzymes. [12][13][14] The CCK peptide family has many functions, [15] it is important in regulating gallbladder contraction and pancreatic enzyme release.…”

Section: Introductionmentioning

confidence: 99%

Compounds Interacting with Cholecystokinin as Potential Drugs Against Excessive Weight Gain and Obesity

et al. 2023

View full text Add to dashboard Cite

Cholecystokinin (CCK) is a peptide family that functions pancreatic enzyme secretion, gallbladder contraction, intestinal motility, satiety, and stomach acid secretion. The CCK peptides are derived from pro-CCK with a specific amino acid sequence (Asp, Tyr, Met, Gly, Trp, Met, Asp, and Phe) at their C-terminus, where the Tyr residue is sulfated. The CCK peptides are ligands of the CCK receptors 1 (CCK1) and 2 (CCK2). In this study, we propose an approach for treating overweight and obese patients, preventing or reducing CCK1 activation using compounds that specifically interact with CCK peptides to regulate their interactions with CCK1. The compounds were selected by molecular docking using a chemical library with the selected residues (Asp, Tyr, Met, Gly, Trp, Met, Asp, and Phe) in CCK. Their effects were evaluated in a diet-induced obese mice model. We show that compounds K2 and K5 decreased and maintained the body weight of the diet-induced obese mice model, respectively, likely by preventing/hindering interactions between CCK peptides and CCK1, modifying its activity. This study demonstrates another approach to treating overweight and obesity by regulating CCK1 functions. The K2 and K5 compounds have properties supporting their continued development as new drugs against these risk factors.

show abstract

Dyslipidemia, Obesity, and Ethnicity in Mexican Children

Cited by 11 publications

References 32 publications

Prevalence and correlates of dyslipidemia in first-episode and drug-naïve major depressive disorder patients with comorbid abnormal glucose metabolism: Sex differences

Prevalence and correlates of dyslipidemia in first-episode and drug-naïve major depressive disorder patients with comorbid abnormal glucose metabolism: Sex differences

Could Naringenin Participate as a Regulator of Obesity and Satiety?

Compounds Interacting with Cholecystokinin as Potential Drugs Against Excessive Weight Gain and Obesity

Contact Info

Product

Resources

About